Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer
- First Online:
- 107 Downloads
We investigated the incidence of secondary leukemia in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced testicular cancer.
Three hundred and twenty-three patients who were entered into two consecutive prospective Phase-II studies of the German Testicular Cancer Study Group were analyzed. A total of 221 patients had received HD-VIP containing cisplatin, ifosfamide, and etoposide and 102 patients were treated with Tax-HD-VIP containing cisplatin, ifosfamide, etoposide, and paclitaxel, each cycle supported by autologous PBSCT.
Patients had received a median cumulative etoposide dose of 4.9 g/m2 (range, 2.2–9.4 g/m2). The median follow-up duration for all patients was 36 months (range, 0–128) with a median follow up time of 50 months (range, 0–128) for patients surviving at least 1 year after therapy. One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13.3) 24 months after the start of chemotherapy resulting in a cumulative incidence of 0.48% [95% confidence interval (CI) 0–1.42]. Additionally, two patients with primary mediastinal germ cell cancer developed a myelodysplastic syndrome. No solid tumors had occurred.
HDCT including high-dose etoposide with autologous PBSCT as first-line therapy for advanced testicular cancer was associated with an acceptably low risk of developing secondary leukemia.
KeywordsSecondary leukemia High-dose chemotherapy Etoposide Germ cell cancer
- 4.Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Nat Cancer Inst 87:58–60Google Scholar
- 5.Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17:3450–3456PubMedGoogle Scholar
- 8.Chevreau C, Droz JP, Pico JL, Biron P, Kerbrat P, Cure H, Heron JF, Chevallier B, Fargeot P, Kramar A (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk nonseminomatous germ cell tumors. Prelimanary results of a French randomized trial. Eur Urol 23:213–217PubMedGoogle Scholar
- 10.Felix CA (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 36:525–535Google Scholar
- 12.Hartmann JT, Schleucher N, Metzner B, Koehne CH, Gerl A, Schleicher J, Rick O, Derigs HG, Beyer J, Boehlke I, Kanz L, Bokemeyer C (2001) Phase I/II study of sequential high dose VIP plus paclitaxel in patients with “poor prognosis” germ cell tumor. Proc Am Soc Clin Oncol 24 [abstr 691]Google Scholar
- 15.Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Fléchon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C (1998a) Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ-cell tumors. J Clin Oncol 16:3386–3391PubMedGoogle Scholar
- 16.Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C (1998b) Risk of secondary leukemia and myelodysplastic syndrome following standard dose chemotherapy or high dose chemotherapy with stemm cell support in patients with potentially curable malignancies. J Cancer Res Clin Onc 124:207–214Google Scholar
- 18.Le Delay MC, Leblanc T, Shamsaldin A, Raquin MA, Lacour B, Sommelet D, Chompret A, Cayuela JM, Bayle C, Bernheim A, de Vathaire F, Vassal G, Hill C (2003) Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d’Oncologie Pediatrique. J Clin Oncol 21:1074–1081PubMedGoogle Scholar
- 20.Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister TA, Rohatiner AZ (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947–55PubMedGoogle Scholar
- 23.Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN (1989) Dose-intensive chemotherapy in refractory germ cell cancer- a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932–939PubMedGoogle Scholar
- 29.Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German testicular cancer study group. J Clin Oncol 21:4083–4091CrossRefPubMedGoogle Scholar
- 31.Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, Prince HM (1999) Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 13:1735–40Google Scholar
- 32.Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT (2001) Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91:1304–1315PubMedGoogle Scholar
- 36.Wierecky J, Kollmannsberger C, Boehlke I, Kuczyk M, Schleicher J, Schleucher N, Metzner B, Kanz L, Hartmann JT, Bokemeyer C (2005) Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol (this issue)Google Scholar